VeriSIM was founded in 2017 by Dr. Jo Varshney, a multi-disciplinary and celebrated leader in veterinary & human health development. Together with a team of world-class scientists, machine learning engineers and in silico simulation experts the team is bringing clarity to drug development through computational sciences rather than the existing trial and error experimentation approach. The leadership believes with their machine learning driven approach, they are able to pre-flight advancements in medicine without the need for redundant trials, subjecting animals to the cruelty of testing, and with far better outcomes than the 8% success currently seen in medicine making it to market. More people will be able to receive the treatments they need and our partners will see faster and verified results from their research.
Humbled & honored to work & learn from an exceptional cross-functional team.
Dr. Barnes is experienced Pharma drug developer with extensive knowledge in AI and drug chemistry.
John Alves is an experienced CFO with over 25 years of finance and operational strategy experience serving both private and public companies in the biotechnology and enterprise software/SaaS markets.
Leads modeling & integration efforts, ensuring that VSL model predictions are accurate, scalable, and translatable.
Ensures the smooth operation of daily activities in the business and efficiently handles all administrative duties.
Solving creative challenges and contributing to human/animal life through AI has inspired Yogesh to be part of VSL's mission.
Jason spearheads complex engineering efforts and manages company goals such that VSL is best positioned for mission success.
Daniel applies theoretical chemistry methods to far-reaching challenges at the interface of chemistry and pharmacology.
With an eye for detail, she strengthens VSL’s growing database to contribute to more humane testing methods in pharmacology.
Kaushik oversees scientific cross-functionality and validity of the computational models in the context of translational research.
Nilesh oversees strategic business development, client and alliance management, and customer acquisition.
Bryan creates robust software systems that deliver insights to the scientific teams working with VSL technology.
Aditya develops mathematical models that aid in the understanding of physiological mechanisms behind complex biological systems.
Maksim leads research and scientific efforts to make BIOiSIM the most accurate predictor of PK/PD/DDI profiles of xenobiotics.
Diversity, Inclusion, and Belonging at VeriSIM Life work very differently than in the industries and world in which we interact. As a ground up approach, we value — with the highest of esteem — the diverse backgrounds, experiences, and knowledge bases that each member of our team represents and brings to VeriSIM Life. By requiring that collaboration and communication come from a place of understanding these differences, we can quickly, with agility and efficiency, navigate through our own environment by fully engaging in the wealth of cognitive diversity that comes from accessing our whole selves.
In doing so, we solve more of the problems standing in front of our mission. We do this through a commitment and practice in leading with questions, offering and receiving feedback that is communicated with identities and communication style taken into consideration. We share cultural experiences together, and have mandated that anyone at VeriSIM Life may escalate concerns to our CEO and depend on one another in times of crisis or whenever one feels unsafe.
Since Day 1, our investors have not only provided the resources we need to accomplish and continue our mission, but have also served as invaluable resources to understand our approach, our organizational process, and the potential of VeriSIM Life.
